Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 Trial.
Genetic patterns beyond standard testing can predict which hormone-receptor-positive breast cancer patients will respond best to a targeted drug combination.
Comprehensive genomic analysis of the SOLAR-1 trial identified co-mutational signatures that predict response and resistance to alpelisib plus fulvestrant in PIK3CA-mutated breast cancer, refining patient selection beyond standard PIK3CA testing. These findings could improve treatment decision-making in HR+/HER2- advanced breast cancer.
What the study was
- Study design
- Genomic analysis of randomized controlled trial (SOLAR-1)
- Population
- PIK3CA-mutated HR+/HER2- advanced breast cancer patients from SOLAR-1 trial
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Annals of Oncology
Why it surfaced
RCT-based genomic analysis in high-impact journal (Ann Oncol) refining precision medicine for a common cancer; directly informs patient selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.